Serial immune evaluation of cyclosporine- and placebo-treated multiple sclerosis patients

Ronald H. Kerman, Jerry S. Wolinsky, Avindra Nath, E. Simon Sears

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


During an ongoing clinical trial of cyclosporine (CsA) immunosuppression therapy for chronic progressive multiple sclerosis (MS), a comparison was made of the immune responses of 18 CsA- and 18 placebo (P)-treated MS patients. Patients randomized to receive either CsA or P had identical entry immune profiles. However, these MS patients displayed significantly increased T-helper: T-suppressor (TH : TS) ratios (P < 0.01), percentage (%) active-T (P < 0.01), % Ia+-T (P < 0.05) and % Ta1+-T (P < 0.01) cell phenotypes when compared to age-matched normal controls. Further, the MS-P-treated patients displayed significant increases (all P < 0.01) in % pan-T, % helper-T, % active-T and % Ta1+-T cell phenotypes as well as panel mixed lymphocyte culture (panel MLC) functional responsiveness from entry to cumulative 12-month study data. In contrast, the MS-CsA-treated patients only displayed an increased % pan-T cell phenotype. The cumulative 12-month follow-up data showed that the MS-P-treated patients displayed significantly higher immune parameters than the MS-CsA-treated patients for % pan-T (P < 0.05), % helper-T (P < 0.01), TH : TS ratio (P < 0.05), % active-T (P < 0.01), % Ta1+-T cells (P < 0.01) and panel MLC stimulation index (P < 0.01). Thus, MS-CsA-treated patients did not display the progressive immune activation seen on serial evaluation during the follow-up time period that characterized the placebo-treated MS group.

Original languageEnglish (US)
Pages (from-to)325-331
Number of pages7
JournalJournal of Neuroimmunology
Issue number4
StatePublished - Jul 1988


  • Immune evaluation
  • Multiple sclerosis
  • serial

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Serial immune evaluation of cyclosporine- and placebo-treated multiple sclerosis patients'. Together they form a unique fingerprint.

Cite this